title: Effect of vasopressin administration and deficiency upon 3H-AVP binding sites in the CNS and periphery during development.
abstract: Arginine8-vasopressin (AVP, 40 micrograms/100 g b.wt., SC) was administered to male Long-Evans (LE) pups from day 1 to 7 of life and the pups were sacrificed on day 8 or 60. 3H-AVP binding was performed on membranes prepared from the liver, kidney, and septum. No significant changes were observed in the kidney or septum of animals 8 or 60 days old. However, the chronic AVP treatment did result in a significant increase in the density of 3H-AVP binding sites in the liver when compared to control day 8 pups (control 44 +/- 2 vs. AVP 56 +/- 3 fmol/mg protein), with no change in affinity. This effect was maintained into adulthood, as the day 60 AVP-treated LE rats also showed a significant increase in liver 3H-AVP binding sites compared to control (control 186 +/- 9 vs. AVP 239 +/- 14 fmol/mg protein), with no change in affinity. A comparison of 3H-AVP binding sites in 8-day-old LE, heterozygous Brattleboro (HET-BB), and homozygous Brattleboro rats (HOM-BB) was performed to assess the effect of complete (HOM-BB) and partial (HET-BB) VP deficiency on binding sites in the CNS and periphery. The liver again was the only tissue in which a change in 3H-AVP binding characteristics was noted. The HOM-BB rat (Bmax 144 +/- 6 fmol/mg protein) displayed a significant increase in AVP binding sites from the LE rat (Bmax 100 +/- 7 fmol/mg protein), while the 3H-AVP binding sites in the HET-BB rat liver (Bmax 69.8 +/- 9 fmol/mg protein) were significantly lower than LE rats. Thus hepatic AVP receptors appear most sensitive to the presence or absence of vasopressin during the early postnatal period.
authors.affiliation: Department of Medicine, University of Washington, Seattle 98195.
authors.forename: P
authors.initials: P
authors.lastname: Szot
authors.forename: K M
authors.initials: KM
authors.lastname: Myers
authors.forename: D M
authors.initials: DM
authors.lastname: Dorsa
mesh_terms: D000818:Animals; D000831:Animals, Newborn / Q000254:growth & development* / Q000378:metabolism; D001127:Arginine Vasopressin / Q000378:metabolism*; D007668:Kidney / Q000737:chemistry / Q000187:drug effects* / Q000254:growth & development; D008099:Liver / Q000737:chemistry / Q000187:drug effects* / Q000254:growth & development; D008297:Male; D051381:Rats; D011910:Rats, Brattleboro; D011919:Rats, Inbred Strains; D011945:Receptors, Angiotensin / Q000032:analysis / Q000187:drug effects*; D017483:Receptors, Vasopressin; D012688:Septum Pellucidum / Q000737:chemistry / Q000187:drug effects* / Q000254:growth & development; D014667:Vasopressins / Q000172:deficiency* / Q000494:pharmacology*
chemical_list: D011945:Receptors, Angiotensin; D017483:Receptors, Vasopressin; D014667:Vasopressins; D001127:Arginine Vasopressin